Press Alt+1 for screen-reader mode, Alt+0 to cancelAccessibility Screen-Reader Guide, Feedback, and Issue Reporting | New window
timothy sykes logo

Stock News

RXRX Stock Surges: What Awaits Next?

Ellis HobbsAvatar
Written by Ellis Hobbs Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 7/25/2025, 5:03 pm ET | 6 min
RXRX Stock Surges: What Awaits Next? Thumbnail

In this article

  • RXRX+1.24%
    RXRX - NYSERecursion Pharmaceuticals Inc.
    $4.89+0.06 (+1.24%)
    Volume:  474157
    Float:  404.63M
    $4.84Day Low/High$4.92

Recursion Pharmaceuticals Inc.’s stocks have been trading up by 3.51 percent amid positive news sentiment.

  • Recursion Pharmaceuticals (RXRX) gained 12% after revealing it bought full interest in a joint program for the REV102 drug candidate with Rallybio, impacting both company’s shares markedly.

  • RXRX shares increased by nearly 12% upon acquiring Rallybio’s stake in a hypophosphatasia treatment program, positioning RXRX favorably for future developments in the treatment.

  • Rallybio surged 50% due to RXRX’s acquisition of a drug candidate, causing RXRX’s shares to climb 10% following the announcement.

Candlestick Chart

Live Update At 17:03:28 EST: On Friday, July 25, 2025 Recursion Pharmaceuticals Inc. stock [NASDAQ: RXRX] is trending up by 3.51%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Overview of RXRX’s Recent Financial Metrics

As millionaire penny stock trader and teacher Tim Sykes says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” For traders seeking to improve their strategies, it’s crucial to understand the importance of consistent, incremental progress rather than aiming for significant, immediate profits. This mindset helps to build a solid foundation in the trading world, reducing the risks associated with high-stakes trades. By focusing on steady growth and learning from each trade, traders can develop a more sustainable and successful approach in the long run.

When breaking down the numbers, RXRX showed some notable movements. The stock’s open on Jul 25, 2025, was $6.20 and it closed at $6.49, showing a positive incline. Beyond the numbers, their financial strength is reflected in their robust ratios like a current ratio of 4.1, which indicates the company can meet its short-term liabilities with its short-term assets comfortably.

However, other numbers reveal a different story. The company reports a negative EBIT margin of -959.9, pointing out that RXRX has faced challenges maintaining profitability. Despite this, RXRX has expanded its footing with a noteworthy collaboration with MIT on the Boltz-2 AI model. Such partnerships aim to push the envelope in drug discovery, indicating bold steps towards future growth.

Breaking down cash flows, RXRX has seen a negative net change of $98.7M in cash, highlighting current capital consumption. Yet, they notably ramped up their stock options by $1.55M, reflecting investor confidence.

Analysis of Key News Articles

RXRX’s Strategic Move with REV102

The highlight of recent weeks focused on RXRX’s pursuit of full rights to REV102. This strategic acquisition is not just a bold move; it’s a calculated gamble at sharpening their edge in treating hypophosphatasia—a rare bone disease. Owning full rights means RXRX holds complete control over its journey from lab to patient, enhancing potential revenue streams.

The market’s reaction was immediate—a jump of 12% in their stock value. This move echoed within Rallybio’s corridors as well, with a 50% surge in their shares—a proxy of aligned investor optimism. One might even argue that this acquisition aligns with intrinsic market gaps, setting RXRX up for fruitful returns.

Financial Stance and Market Speculations

Assessing RXRX’s financial contour unveils a multifaceted picture. The net losses positioned at $202 million reflect ongoing investments, common in evolving pharmaceutical entities. Meanwhile, revenues surged by about 297% over five years—numbers capturing growth aspiration amidst inherent risks.

Between charts and figures, RXRX’s enterprise value sits at $2.137 billion. Consequently, their current liabilities of $142 million can be comfortably matched by their assets. Yet, their challenge lies in leveraging such assets into long-term profitable ventures.

With AI as an anchor, RXRX partners with MIT to innovate molecule prediction, marked by their Boltz-2 endeavor. It speaks to an ambitious mindset, one that finds convergence between big data and drug discovery, fostering optimism for newer, more lucrative horizons.

In pondering the landscape of RXRX’s financial symphony, few can dismiss the tidings of potential multi-fold upside. Scores, while indicating caution in profitability, carry glimpses of resilience buoyed by strategic acquisitions and partnerships.

More Breaking News

Impact of the Acquisitions on RXRX

The surge in RXRX’s shares encapsulates investor sentiment upon news releases. The market’s marked optimism stems from enhanced control over REV102’s future, allowing RXRX to mitigate dependency risks and potentially shorten timetables from development phase to market stage.

Each speculation about RXRX’s future may appear lofty, yet observers recognize opportunities looming over treatment paradigms, aided by tools like AI. Futuristic yet pragmatic, RXRX represents a narrative of how strategic maneuvers and calculated risks stand poised to define its trajectory—its chapters penned upon the study of pivotal numbers and strategic acquisitions. As millionaire penny stock trader and teacher Tim Sykes, says, “Small gains add up over time; focus on building wealth gradually, not chasing jackpots.” This perspective underscores the approach traders might adopt while navigating RXRX’s strategic moves in the volatile market landscape.

In conclusion, as RXRX progresses, new chapters await. The mosaic of past lessons, current maneuvers, and future aspirations coalesce toward prosperity, but seasoned traders approach with measured optimism, conscious of the intricate dance between numbers, strategies, and market responses.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Ellis Hobbs

Trainer and Mentor on Tim Sykes’ Trading Challenge
He teaches webinars on Tim Sykes’ Trading Challenge He treats trading like a business, not a hobby He emphasizes taking small risks — “If you get the process right, money is a forgone conclusion.”
Read More

In this article (YTD Performance)

  • RXRX-28.55%
    RXRX - NYSERecursion Pharmaceuticals Inc.
    $4.89+0.06 (+1.24%)
    Volume:  474157
    Float:  404.63M
    $4.84Day Low/High$4.92

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”

ts swipe photo
Get Tim Sykes’ Daily Trade Ideas for $0
Claim Free Alerts

We use cookies to provide you with the best online experience. If you continue browsing, we consider that you accept our Cookie Policy , and also agree to the terms of our Privacy Policy and Terms of Use.